Nemes Rush Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Nemes Rush Group’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$40.3K	Hold	2,000	–	–	﹤0.01%	381
2026 Q2	$50.6K	Hold	2,000	–	–	﹤0.01%	373
2026 Q1	$44.5K	Hold	2,000	–	–	﹤0.01%	371
2025 Q4	$53.4K	Hold	2,000	–	–	0.01%	339
2025 Q3	$42.7K	Hold	2,000	–	–	﹤0.01%	346
2025 Q2	$43.1K	Hold	2,000	–	–	﹤0.01%	349
2025 Q1	$33.2K	Hold	2,000	–	–	﹤0.01%	361
2024 Q4	$36.7K	Hold	2,000	–	–	﹤0.01%	339
2024 Q3	$37K	Hold	2,000	–	–	0.01%	295
2024 Q2	$32.5K	Hold	2,000	–	–	﹤0.01%	303
2024 Q1	$37K	Hold	2,000	–	–	0.01%	320
2023 Q4	$62.6K	Hold	2,000	–	–	0.01%	243
2023 Q3	$41.7K	Hold	2,000	–	–	0.01%	272
2023 Q2	$47.9K	Buy	+2,000	New	+$44.5K	0.01%	268

Other funds holding ACAD

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Nemes Rush Group's ACAD Position: Q3 2026 in Review

Nemes Rush Group held its Acadia Pharmaceuticals (ACAD) position steady in Q3 2026 at 2,000 shares worth $40.3K. The position accounts for ﹤0.01% of the portfolio, ranked #381.

Nemes Rush Group first reported a position in ACAD in Q2 2023 and has held it in 14 quarters since. The position peaked at $62.6K in Q4 2023. 153 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.

Nemes Rush Group held 2,000 shares of Acadia Pharmaceuticals worth $40.3K as of Q3 2026.
Nemes Rush Group left its Acadia Pharmaceuticals share count unchanged in Q3 2026.
Acadia Pharmaceuticals made up ﹤0.01% of Nemes Rush Group's portfolio in Q3 2026, its #381 holding.
Nemes Rush Group first reported a position in Acadia Pharmaceuticals in Q2 2023 and has held it in 14 quarters since.
Nemes Rush Group's Acadia Pharmaceuticals position peaked at $62.6K in Q4 2023.
153 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.

Based on Nemes Rush Group's 13F filing for Q3 2026, filed 4 Nov 2026.